BioChem Adda

@BioChemAdda | BioTech Adda -  No. 1 #Jobs, #Events, & #News Portal. #Biotech Jobs, Biotech #Vacancy, Biotech #Naukri, #Chemistry Jobs, #Biosciences #Careers.

[BioChem Adda @BioChemAdda]

Future proof your biotech career with the required skills - Admissions Open - Biocon KGI Certificate Program in Biosciences - https://t.co/SOzWsgV0Kf

[BioChem Adda @BioChemAdda]

Just posted a photo https://t.co/ZzCndBoV9r

[BioChem Adda @BioChemAdda]

Learn the applied knowledge on various Good Regulatory Practices (GRA) - Admissions Open for Certificate Program in GRA - https://t.co/vJi2T3zlyI

[BioChem Adda @BioChemAdda]

Biocon Ramaiah Certificate Program in QC Analytical, Batch 3 - https://t.co/vpbcZJ2Cge

Please mention @BioChemAdda while applying to this program.

https://t.co/S3iuxJyNwg)

[BioChem Adda @BioChemAdda]

Just posted a photo https://t.co/GWIjCfl2ui

[BioChem Adda @BioChemAdda]

$ARVN - Arvinas to Present at the Guggenheim Healthcare Talks: 2021 Oncology Day

https://t.co/4Z4wJGDOEn

[BioChem Adda @BioChemAdda]

$AUTL - Autolus Announces Proposed Public Offering in the United States

https://t.co/53pBXLeykY

[BioChem Adda @BioChemAdda]

$CSII - First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

https://t.co/and9YNjz8m

[BioChem Adda @BioChemAdda]

$CORT - Corcept Therapeutics Announces Fourth Quarter, Full-Year 2020 Preliminary Selected Financial Results and 2021 Revenue Guidance; Provides Corporate Update

https://t.co/Yfu5UDUdk7

[BioChem Adda @BioChemAdda]

$NAVB - Navidea Biopharmaceuticals Announces Submission of Formal Type B Meeting Request with FDA and Launch of NAV3-32 Phase 2B Trial in Rheumatoid Arthritis

https://t.co/XQg2jE4U5e

[BioChem Adda @BioChemAdda]

$AVIR - Atea Pharmaceuticals Announces Publication of Preclinical Data Highlighting Potent Activity of AT-527 Against SARS-CoV-2

https://t.co/lksXCPxP8w

[BioChem Adda @BioChemAdda]

$RVMD - Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

https://t.co/0a5VpoXM7S

[BioChem Adda @BioChemAdda]

$IRWD - Ironwood Pharmaceuticals Announces CEO Transition

https://t.co/7ckHFhAorr

[BioChem Adda @BioChemAdda]

$ENTA - Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET

https://t.co/SMAblhM9KM

[BioChem Adda @BioChemAdda]

$BXRX - Baudax Bio Announces $17.6 Million Offering Priced At-the-Market under Nasdaq Rules

https://t.co/4TyzZEmzVH

[BioChem Adda @BioChemAdda]

$SRNE - Sorrento Announces Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Hematological Malignancies and Solid Tumors Based on an Exclusive Technology License From the Mayo Clinic - manufacture of antibody-drug conjugates (ADC)

[BioChem Adda @BioChemAdda]

$FOLD - Amicus Therapeutics Announces Positive Initial Clinical Data for CLN3 Batten Disease Gene Therapy at the 17th Annual WORLDSymposium™ 2021

[Seeking Alpha Market Currents @MarketCurrents]

$FOLD - Amicus announces early-stage interim data for AT-GTX-502 in Batten disease https://t.co/vgLfZBn2Bl

[BioChem Adda @BioChemAdda]

#biowar $SRNE Prospects Look Bright.

Several COVID-19 therapeutics plus diagnostic tests.

[BioChem Adda @BioChemAdda]

Hey @WSBChairman...

please suggest...

$srne is it worth (to the moon).

Currently in $12-13 range. But few analysts project it to be worth of $35.

[NK Singh @nsmalhan]

A recent study coming from #France found no evidence of a strong antiviral activity or clinical benefit of the combination of #hydroxychloroquine and #azithromycin for the treatment of hospitalized patients with severe #COVID19

#coronavirus #COVID

https://t.co/wPJbQ93TSu